Imaging AI in Nebraska

Bot Image, Inc. is an FDA-cleared AI software company specializing in prostate cancer detection, screening, and diagnosis using bi-parametric MRI (bpMRI). The company's flagship product, ProstatID, is a CADe/CADx (Computer-Aided Detection and Diagnosis) software designed to assist radiologists in detecting, assessing, and characterizing prostate lesions suspicious for cancer. ProstatID is vendor-agnostic and integrates seamlessly with existing PACS systems from major OEMs (Philips, Siemens, GE) without requiring additional equipment or user intervention. The software delivers AI-generated results within minutes, providing physicians with lesion segmentation, risk scoring aligned to Gleason grades, and 3D visualization for treatment planning. Bot Image also offers MaleScan, a direct-to-patient/physician cloud-based service enabling rapid AI-assisted diagnostic reporting. The company's AI models are trained on over 1,000 biopsied cases with 6,000+ biopsy confirmation points, demonstrating significantly improved diagnostic accuracy and inter-reader agreement in clinical studies. Solutions address key pain points including interpretation complexity, reading time reduction, cost efficiency via non-contrast imaging, and improved clinical outcomes for prostate cancer screening and early detection.

Vitazi.ai is a software and AI analytics company specializing in oculomics—the extraction of systemic health biomarkers from retinal imaging. The platform transforms routine retinal scans into multi-disease screening tools, detecting early signs of diabetic retinopathy, glaucoma, age-related macular degeneration (AMD), hypertensive retinopathy, cardiovascular disease risk factors, and neurological disorder indicators. The solution operates as a cloud-based service accessible via secure API with EHR integration, designed for optometrists, primary care practices, health systems, and telehealth networks. Vitazi offers a tiered product approach: AI-only screening for single conditions (diabetic retinopathy, glaucoma, AMD); telehealth-enabled staging with specialist oversight; and proprietary oculomics technology combining quantitative retinal analysis with systemic risk assessment (not yet FDA cleared). The company targets the growing preventive care market, leveraging the fact that over 60% of U.S. optometry practices already possess retinal imaging equipment, eliminating infrastructure barriers. Clinical backing is rooted in 21,000+ peer-reviewed publications on oculomics since 2020. Key value propositions include new reimbursable CPT codes (92250) for optometrists, improved HEDIS/STAR/MIPS quality metrics for health systems, and earlier disease detection for chronic conditions. The platform includes built-in specialist referral networks and guidance on clinical next steps. Vitazi positions itself at the intersection of rising chronic disease prevalence, provider shortage projections (35,000 PCPs and 81,000 specialists by 2035), and the emerging digital biomarkers market (projected $14B by 2030).